Structure-based drug design of novel potent and selective tetrahydropyrazolo[1,5-a]pyrazines as ATR inhibitors

ACS Medicinal Chemistry Letters

Volumn 6, Issue 1, 2015, Pages 37-41

  Barsanti, Paul A ^a,b   Aversa, Robert J ^a   Jin, Xianming ^a   Pan, Yue ^a   Lu, Yipin ^a   Elling, Robert ^a   Jain, Rama ^a   Knapp, Mark ^a   Lan, Jiong ^a   Lin, Xiaodong ^a   Rudewicz, Patrick ^a   Sim, Janet ^a   Taricani, Lorena ^a   Thomas, George ^a   Xiao, Linda ^a   Yue, Qin ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Nurix Inc   (United States)

Author keywords

ATR; CYP3A4 TDI; deuterium; Fsp3; structure based drug design

Indexed keywords

ATR PROTEIN; ATR PROTEIN INHIBITOR; CYANIDE; CYTOCHROME P450 3A4; GLUTATHIONE; PROTEIN INHIBITOR; PYRAZINE DERIVATIVE; TETRAHYDROPYRAZOLO[1,5 A]PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; HYDROGEN BOND; HYDROGENATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STATIC ELECTRICITY;

EID: 84920722466     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500353p     Document Type: Article

References (15)

1. Weinert, T. A. DNA damage checkpoint meets the cell cycle engine. Science 1997, 277, 1450-1451.
2. Hartwell, L. H.; Weinert, T. A. Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246, 629-634.
3. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer. Nature 2004, 432, 316-323.
4. Bartek, J.; Lukas, C.; Lukas, J. Checking on DNA damage in S phase. Nat. Rev. Mol. Cell Biol. 2004, 5, 792-804.
5. Cimprich, K. A.; Cortez, D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 2008, 9, 616-627.
6. Toledo, L. I.; Murga, M.; Fernandez-Capetillo, O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol. Oncol. 2011, 5, 368-373.
7. McNeely, S.; Beckmann, R.; Bence Lin, A. K. CHEK again: revisiting the development of Chk1 inhibitors for cancer therapy. Pharmacol. Ther. 2014, 142, 1-10.
8. Foote, K. M.; Blades, K.; Cronin, A.; Fillery, S.; Guichard, S. S.; Hassall, L.; Hickson, I.; Jacq, X.; Jewsbury, P. J.; McGuire, T. M.; Nissink, J. W. M.; Odedra, R.; Page, K.; Perkins, P.; Suleman, A.; Tam, K.; Thommes, P.; Broadhurst, R.; Wood, C. Discovery of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J. Med. Chem. 2013, 56, 2125-2138.
9. Charrier, J. D.; Durrant, S. J.; Golec, J. M. C.; Kay, D. P.; Knegtel, R. M. A.; MacCormick, S.; Mortimore, M.; O'Donnell, M. E.; Pinder, J. L.; Reaper, P. M.; Rutherford, A. P.; Wang, P. S. H.; Young, S. C.; Pollard, J. R. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 2011, 54, 2320-2330.
10. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 2009, 52, 6752-6756.
11. Barsanti, P. A.; Crawford, K.; Doyle, M. V.; Elling, R.; Knapp, M.; Lu, Y.; Sim, J.; Warne, B.; Yan, K.; Zhang, L. Engineering of chimeric PI3Kα proteins sensitive to small molecule inhibitors targeting ATR. Manuscript in preparation.
12. Surry, D. S.; Buchwald, S. L. Dialkylbiaryl phosphines in Pdcatalyzed aminatino: a user's guide. Chem. Sci. 2011, 2, 27-49.
13. Hollenberg, P. F.; Kent, U. M.; Bumpus, N. N. Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications. Chem. Res. Toxicol. 2008, 21, 189-205.
14. Wong, S. J.; Fan, P. W.; Subramanian, R.; Tonn, G. R.; Henne, K. R.; Johnson, M. G.; Lohr, M. T.; Wong, B. K. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/Dprostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction. Drug Metab. Dispos. 2010, 38, 841-850.
15. Menezes D. L.; Holt, J.; Tang, Y.; Feng, J. F.; Barsanti, P.; Pan, Y.; Ghoddusi, M.; Zang, W.; Holash, J.; Lees, E.; Taricani, L. Mol. Cancer Res.; DOI: 10.1158/1541-7786.MCR-14-0240.